The Jones Institute Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2014
NCT02210702
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Jones Institute, Norfolk VA 23507

Active Ingredients

Drugs in Phase 4 Trials (2)

ethinyl estradiol (Estinyl) (1 trial)

norethindrone (1 trial)

Drugs in Phase 3 Trials (1)

prasterone (intrarosa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 3)

Breast Neoplasms (Phase 3)

Depression (Phase 4)

Depression, Postpartum (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 3